EA201170475A1 - Иммунотерапевтические средства против комплекса tcr - Google Patents
Иммунотерапевтические средства против комплекса tcrInfo
- Publication number
- EA201170475A1 EA201170475A1 EA201170475A EA201170475A EA201170475A1 EA 201170475 A1 EA201170475 A1 EA 201170475A1 EA 201170475 A EA201170475 A EA 201170475A EA 201170475 A EA201170475 A EA 201170475A EA 201170475 A1 EA201170475 A1 EA 201170475A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- immunotherapy
- tcr complex
- medicines against
- against tcr
- medicines
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 abstract 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
Abstract
Предложен одноцепочечный гибридный белок, который специфично связывается с комплексом TCR или его компонентом, таким как TCRα, TCRβ или CD3ε, а также композиции и способы применения такого белка.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10460808P | 2008-10-10 | 2008-10-10 | |
US14834109P | 2009-01-29 | 2009-01-29 | |
PCT/US2009/060286 WO2010042904A2 (en) | 2008-10-10 | 2009-10-09 | Tcr complex immunotherapeutics |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201170475A1 true EA201170475A1 (ru) | 2012-06-29 |
EA032828B1 EA032828B1 (ru) | 2019-07-31 |
Family
ID=41650152
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201170475A EA032828B1 (ru) | 2008-10-10 | 2009-10-09 | Иммунотерапевтические средства против комплекса tcr |
Country Status (13)
Country | Link |
---|---|
US (3) | US20110217302A1 (ru) |
EP (1) | EP2356150A2 (ru) |
JP (3) | JP2012504970A (ru) |
KR (2) | KR20180105736A (ru) |
CN (2) | CN105218673A (ru) |
AU (1) | AU2009303318B2 (ru) |
BR (1) | BRPI0920573A8 (ru) |
CA (1) | CA2740098A1 (ru) |
EA (1) | EA032828B1 (ru) |
MX (1) | MX2011003763A (ru) |
NZ (2) | NZ603623A (ru) |
SG (1) | SG172754A1 (ru) |
WO (1) | WO2010042904A2 (ru) |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
JP5686953B2 (ja) * | 2005-10-11 | 2015-03-18 | アムゲン リサーチ (ミュンヘン) ゲーエムベーハー | 交差種特異的(cross−species−specific)抗体を含む組成物および該組成物の使用 |
JP5624276B2 (ja) | 2006-03-31 | 2014-11-12 | 中外製薬株式会社 | 抗体の血中動態を制御する方法 |
JP5334319B2 (ja) | 2007-09-26 | 2013-11-06 | 中外製薬株式会社 | Cdrのアミノ酸置換により抗体の等電点を改変する方法 |
BRPI0914005A2 (pt) * | 2008-07-02 | 2015-11-17 | Emergent Product Dev Seattle | proteínas antagonistas tnf-alfa de ligação a alvos múltiplos |
AU2009266856A1 (en) * | 2008-07-02 | 2010-01-07 | Emergent Product Development Seattle, Llc | IL6 immunotherapeutics |
DK2344540T3 (da) | 2008-10-02 | 2018-01-29 | Aptevo Res & Development Llc | Cd86-antagonist multimål bindingsproteiner |
WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
RU2673908C2 (ru) | 2009-12-02 | 2018-12-03 | Имэджинэб, Инк. | Мини-антитела j591 и цис-диатела для направленной доставки простата-специфичного мембранного антигена (psma) человека и способы их применения |
US20130052195A1 (en) | 2009-12-23 | 2013-02-28 | Emergent Product Development Seattle,LLC | Compositions Comprising TNF-alpha and IL-6 Antagonists and Methods of Use Thereof |
JP5764921B2 (ja) | 2009-12-24 | 2015-08-19 | Jnc株式会社 | 発光活性を有する融合蛋白質 |
EP3112382A1 (en) * | 2009-12-29 | 2017-01-04 | Emergent Product Development Seattle, LLC | Heterodimer binding proteins and uses thereof |
AU2011283694B2 (en) | 2010-07-29 | 2017-04-13 | Xencor, Inc. | Antibodies with modified isoelectric points |
EA201390575A1 (ru) | 2010-10-29 | 2014-01-30 | Иммьюноджен, Инк. | Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты |
SG189929A1 (en) | 2010-10-29 | 2013-06-28 | Immunogen Inc | Novel egfr-binding molecules and immunoconjugates thereof |
TWI638833B (zh) | 2010-11-30 | 2018-10-21 | 中外製藥股份有限公司 | 細胞傷害誘導治療劑 |
MY171343A (en) * | 2011-04-22 | 2019-10-09 | Aptevo Res & Development Llc | Prostate-specific membrane antigen binding proteins and related composition and methods |
EP2714733B1 (en) | 2011-05-21 | 2019-01-23 | MacroGenics, Inc. | Cd3-binding molecules capable of binding to human and non-human cd3 |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
WO2013067517A2 (en) | 2011-11-03 | 2013-05-10 | Tolera Therapeutics.Inc | Antibody and methods for selective inhibition of t-cell responses |
US20130273089A1 (en) | 2011-11-03 | 2013-10-17 | Tolera Therapeutics, Inc. | Antibody and methods for selective inhibition of t-cell responses |
CN104066481A (zh) | 2011-11-21 | 2014-09-24 | 伊缪诺金公司 | 利用egfr抗体细胞毒性剂缀合物治疗抗egfr疗法的肿瘤的方法 |
RU2673153C2 (ru) | 2012-04-20 | 2018-11-22 | АПТЕВО РИСЁРЧ ЭНД ДИВЕЛОПМЕНТ ЭлЭлСи | Полипептиды, связывающиеся с cd3 |
US10301389B2 (en) * | 2012-06-15 | 2019-05-28 | Imaginab, Inc. | Antigen binding constructs to CD3 |
JP6571527B2 (ja) | 2012-11-21 | 2019-09-04 | ウーハン ワイゼットワイ バイオファルマ カンパニー リミテッドWuhan Yzy Biopharma Co., Ltd. | 二重特異性抗体 |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
EP3620473A1 (en) | 2013-01-14 | 2020-03-11 | Xencor, Inc. | Novel heterodimeric proteins |
EP2945969A1 (en) | 2013-01-15 | 2015-11-25 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
EP3421495A3 (en) | 2013-03-15 | 2019-05-15 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
CA2918795A1 (en) * | 2013-07-25 | 2015-01-29 | Cytomx Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
WO2015046467A1 (ja) | 2013-09-27 | 2015-04-02 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
GB201317928D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Molecule |
JP6585600B2 (ja) * | 2013-12-23 | 2019-10-02 | ザイムワークス インコーポレイティド | C末端軽鎖ポリペプチド伸長を含有する抗体、ならびにその複合体及びその使用方法 |
UA119167C2 (uk) | 2014-03-28 | 2019-05-10 | Зенкор, Інк. | Біспецифічне антитіло, яке зв'язується з cd38 та cd3 |
MX2016017393A (es) | 2014-07-01 | 2017-09-05 | Pfizer | Diacuerpos heterodimericos biespecificos y sus usos. |
EP3172235A2 (en) | 2014-07-25 | 2017-05-31 | Cytomx Therapeutics Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
MA40764A (fr) * | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
CN107406512A (zh) | 2014-11-26 | 2017-11-28 | Xencor公司 | 结合cd3和cd38的异二聚体抗体 |
EP3223845B1 (en) | 2014-11-26 | 2021-05-19 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd20 |
WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
WO2016141387A1 (en) | 2015-03-05 | 2016-09-09 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
JP7082484B2 (ja) | 2015-04-01 | 2022-06-08 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
CN106397592A (zh) | 2015-07-31 | 2017-02-15 | 苏州康宁杰瑞生物科技有限公司 | 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白 |
CA2994951A1 (en) | 2015-08-07 | 2017-02-16 | Imaginab, Inc. | Antigen binding constructs to target molecules |
CA2999138C (en) | 2015-09-21 | 2024-05-21 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
KR20180085800A (ko) | 2015-12-07 | 2018-07-27 | 젠코어 인코포레이티드 | Cd3 및 psma에 결합하는 이종이합체성 항체 |
EP3202783A1 (en) * | 2016-02-02 | 2017-08-09 | Ecole Polytechnique Federale de Lausanne (EPFL) | Engineered antigen presenting cells and uses thereof |
RU2746754C2 (ru) | 2016-03-14 | 2021-04-20 | Чугаи Сейяку Кабусики Кайся | Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии |
MA45255A (fr) | 2016-06-14 | 2019-04-17 | Xencor Inc | Anticorps inhibiteurs de points de contrôle bispécifiques |
AU2017290086A1 (en) | 2016-06-28 | 2019-01-24 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
SG11201903302UA (en) | 2016-10-14 | 2019-05-30 | Xencor Inc | Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments |
WO2018147960A1 (en) | 2017-02-08 | 2018-08-16 | Imaginab, Inc. | Extension sequences for diabodies |
US20180252729A1 (en) * | 2017-03-06 | 2018-09-06 | University Of Louisville Research Foundation | Methods and compositions for determining the potency of a therapeutic cellular composition |
JP2020529832A (ja) | 2017-06-30 | 2020-10-15 | ゼンコア インコーポレイテッド | IL−15/IL−15Rαおよび抗原結合ドメインを含む標的化ヘテロダイマーFc融合タンパク質 |
WO2019045856A1 (en) * | 2017-08-28 | 2019-03-07 | Systimmune, Inc. | ANTI-CD ANTIBODIES AND METHODS OF MAKING AND USING THEM |
SG11202002384VA (en) | 2017-10-14 | 2020-04-29 | Cytomx Therapeutics Inc | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
CA3082383A1 (en) | 2017-11-08 | 2019-05-16 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-pd-1 sequences |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
WO2019125732A1 (en) | 2017-12-19 | 2019-06-27 | Xencor, Inc. | Engineered il-2 fc fusion proteins |
CA3096052A1 (en) | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
US11524991B2 (en) | 2018-04-18 | 2022-12-13 | Xencor, Inc. | PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof |
CN112437777A (zh) | 2018-04-18 | 2021-03-02 | Xencor股份有限公司 | 包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白 |
KR20210030378A (ko) * | 2018-07-10 | 2021-03-17 | 리제너론 파마슈티칼스 인코포레이티드 | 기존 상호작용을 최소화하는 결합 분자의 변형 |
CA3115096A1 (en) | 2018-10-03 | 2020-04-09 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
EP3930850A1 (en) | 2019-03-01 | 2022-01-05 | Xencor, Inc. | Heterodimeric antibodies that bind enpp3 and cd3 |
WO2020201527A1 (en) * | 2019-04-04 | 2020-10-08 | Umc Utrecht Holding B.V. | Modified immune receptor constructs |
WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
US20220372147A1 (en) * | 2019-09-25 | 2022-11-24 | Universität Stuttgart | Binding modules comprising modified ehd2 domains |
CN111320703A (zh) * | 2020-03-11 | 2020-06-23 | 北京双赢科创生物科技有限公司 | 靶向cd22的嵌合抗原受体及其应用 |
US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
IL300666A (en) | 2020-08-19 | 2023-04-01 | Xencor Inc | ANTI–CD28 COMPOSITIONS |
IL303328A (en) | 2020-12-01 | 2023-07-01 | Aptevo Res & Development Llc | CD3-binding bispecific and heterodimeric antibodies to PSMA |
WO2022192403A1 (en) | 2021-03-09 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
EP4305065A1 (en) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5637481A (en) * | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US20030108548A1 (en) | 1993-06-01 | 2003-06-12 | Bluestone Jeffrey A. | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
US5885573A (en) * | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
ATE277081T1 (de) * | 1994-01-11 | 2004-10-15 | Dyax Corp | Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten |
US5731168A (en) * | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5834597A (en) * | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
JP4219985B2 (ja) * | 1996-07-23 | 2009-02-04 | タノックス ファーマ ベスローテン フェンノートシャップ | 二つの共刺激経路を同時にブロックできる可溶性分子を用いたt細胞寛容の誘導 |
AU2719099A (en) * | 1998-01-23 | 1999-08-09 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Multipurpose antibody derivatives |
AUPP221098A0 (en) * | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) * | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US20040058445A1 (en) * | 2001-04-26 | 2004-03-25 | Ledbetter Jeffrey Alan | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB |
US20040044182A1 (en) * | 2001-09-17 | 2004-03-04 | Hunt Joan S | Expression, preparation,uses, and sequence of recombinantly-derived soluble hla-g |
KR100960560B1 (ko) * | 2002-09-27 | 2010-06-03 | 젠코어 인코포레이티드 | 최적화된 Fc 변이체 및 그의 제조 방법 |
US7754209B2 (en) * | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
NZ573132A (en) * | 2006-06-06 | 2012-05-25 | Glaxo Group Ltd | Administration of anti-cd3 antibodies in the treatment of autoimmune diseases |
KR101571027B1 (ko) * | 2006-06-12 | 2015-11-23 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | 효과기 기능을 갖는 단일쇄 다가 결합 단백질 |
BRPI0713426A2 (pt) * | 2006-06-14 | 2012-10-09 | Macrogenics Inc | métodos de tratar, diminuir a progressão, ou melhorar um ou mais sintomas de um distúrbio, e de prevenir ou retardar o inìcio de um distúrbio |
CA2673470A1 (en) * | 2006-12-21 | 2008-07-03 | Macrogenics, Inc. | Methods for the treatment of lada and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity |
EP2167130A2 (en) * | 2007-07-06 | 2010-03-31 | Trubion Pharmaceuticals, Inc. | Binding peptides having a c-terminally disposed specific binding domain |
JP2011526794A (ja) * | 2008-07-02 | 2011-10-20 | エマージェント プロダクト デベロップメント シアトル, エルエルシー | TGF−βアンタゴニスト多重標的結合性分子 |
AU2009266856A1 (en) * | 2008-07-02 | 2010-01-07 | Emergent Product Development Seattle, Llc | IL6 immunotherapeutics |
BRPI0914005A2 (pt) * | 2008-07-02 | 2015-11-17 | Emergent Product Dev Seattle | proteínas antagonistas tnf-alfa de ligação a alvos múltiplos |
EP2321345A1 (en) * | 2008-07-28 | 2011-05-18 | Emergent Product Development Seattle, LLC | Multi-specific binding proteins targeting b cell disorders |
DK2344540T3 (da) * | 2008-10-02 | 2018-01-29 | Aptevo Res & Development Llc | Cd86-antagonist multimål bindingsproteiner |
US20130052195A1 (en) * | 2009-12-23 | 2013-02-28 | Emergent Product Development Seattle,LLC | Compositions Comprising TNF-alpha and IL-6 Antagonists and Methods of Use Thereof |
-
2009
- 2009-10-09 CA CA2740098A patent/CA2740098A1/en not_active Abandoned
- 2009-10-09 KR KR1020187026738A patent/KR20180105736A/ko not_active Application Discontinuation
- 2009-10-09 WO PCT/US2009/060286 patent/WO2010042904A2/en active Application Filing
- 2009-10-09 JP JP2011531236A patent/JP2012504970A/ja active Pending
- 2009-10-09 CN CN201510679112.9A patent/CN105218673A/zh active Pending
- 2009-10-09 EA EA201170475A patent/EA032828B1/ru not_active IP Right Cessation
- 2009-10-09 KR KR1020117010643A patent/KR101901458B1/ko active IP Right Grant
- 2009-10-09 MX MX2011003763A patent/MX2011003763A/es not_active Application Discontinuation
- 2009-10-09 EP EP09740584A patent/EP2356150A2/en not_active Withdrawn
- 2009-10-09 SG SG2011025608A patent/SG172754A1/en unknown
- 2009-10-09 NZ NZ603623A patent/NZ603623A/en not_active IP Right Cessation
- 2009-10-09 BR BRPI0920573A patent/BRPI0920573A8/pt active Search and Examination
- 2009-10-09 CN CN2009801500257A patent/CN102292352A/zh active Pending
- 2009-10-09 AU AU2009303318A patent/AU2009303318B2/en not_active Ceased
- 2009-10-09 NZ NZ592611A patent/NZ592611A/xx not_active IP Right Cessation
- 2009-10-09 US US13/123,509 patent/US20110217302A1/en not_active Abandoned
-
2013
- 2013-03-14 US US13/830,959 patent/US20130189261A1/en not_active Abandoned
-
2014
- 2014-09-04 JP JP2014179868A patent/JP5955913B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-10 US US15/040,744 patent/US20170008960A1/en not_active Abandoned
- 2016-04-13 JP JP2016080105A patent/JP2016145244A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2010042904A3 (en) | 2010-08-19 |
KR101901458B1 (ko) | 2018-09-21 |
AU2009303318A2 (en) | 2011-11-10 |
JP2012504970A (ja) | 2012-03-01 |
BRPI0920573A2 (pt) | 2015-12-29 |
NZ592611A (en) | 2013-01-25 |
MX2011003763A (es) | 2011-04-27 |
US20170008960A1 (en) | 2017-01-12 |
SG172754A1 (en) | 2011-08-29 |
US20130189261A1 (en) | 2013-07-25 |
JP5955913B2 (ja) | 2016-07-20 |
KR20110074900A (ko) | 2011-07-04 |
EA032828B1 (ru) | 2019-07-31 |
CN105218673A (zh) | 2016-01-06 |
US20110217302A1 (en) | 2011-09-08 |
BRPI0920573A8 (pt) | 2017-12-12 |
AU2009303318A1 (en) | 2010-04-15 |
JP2014227419A (ja) | 2014-12-08 |
CN102292352A (zh) | 2011-12-21 |
JP2016145244A (ja) | 2016-08-12 |
AU2009303318B2 (en) | 2016-06-30 |
EP2356150A2 (en) | 2011-08-17 |
CA2740098A1 (en) | 2010-04-15 |
NZ603623A (en) | 2014-05-30 |
WO2010042904A2 (en) | 2010-04-15 |
KR20180105736A (ko) | 2018-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201170475A1 (ru) | Иммунотерапевтические средства против комплекса tcr | |
CY1120707T1 (el) | Anti-cd28 εξανθρωπισμενα αντισωματα | |
EA201170396A1 (ru) | 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции | |
EA202190619A1 (ru) | Противовирусные соединения | |
EA201270720A1 (ru) | Модуляторы рецептора андрогенов и их применение | |
EA201391175A1 (ru) | Гетеродимерные иммуноглобулины | |
EA201370066A1 (ru) | Модуляторы эстрогеновых рецепторов и их применение | |
EA201400579A1 (ru) | Антитела к il-36r | |
CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
EA201590993A1 (ru) | Гетеродимерные иммуноглобулины | |
EA201491161A1 (ru) | Фторированные модуляторы рецепторов эстрогенов и их применение | |
EA201391489A1 (ru) | Композиции со сниженной вязкостью | |
EA201491811A1 (ru) | АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ | |
EA201171151A1 (ru) | Кристаллические трипептидные ингибиторы эпоксикетон-протеазы | |
EA201591166A1 (ru) | Ингибиторы аутотаксина | |
EA201270254A1 (ru) | Производные 5-фторпиримидинона | |
EA201391540A1 (ru) | Агонисты fgfr1 и способы их применения | |
EA201591527A1 (ru) | Новые производные пиридина | |
EA201600506A1 (ru) | КРИСТАЛЛИЧЕСКИЙ КОМПЛЕКС 1-ЦИАНО-2-(4-ЦИКЛОПРОПИЛБЕНЗИЛ)-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)БЕНЗОЛА, СПОСОБЫ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ | |
UA118332C2 (uk) | Білок, що зв'язує антиген cd27l | |
EA200970247A1 (ru) | Способ получения оптического активного n-защищенного 3-аминопирролидина или оптически активного n-защищенного 3-аминопиперидина и соответствующих кетонов путем оптического разделения рацемических смесей аминов с использованием бактериальной омега-трансаминазы | |
EA201790963A1 (ru) | Противовирусные соединения | |
EA201490567A1 (ru) | Новые бициклические производные дигидрохинолин-2-она | |
EA201390669A1 (ru) | Способы и композиции для иммунотерапии заболеваний нервной системы | |
EA201391274A1 (ru) | Аминохинолины в качестве ингибиторов киназ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |